1-866-598-7166

A Study of Relatlimab Alone or in Combination with Nivolumab for Patients with Advanced Solid Tumours

Trial ID: NCT01968109
Kidney Cancer Type: Any


Background:

This study involves a number of different medications.

Relatlimab is an experimental immunotherapy drug that works by blocking a molecule called LAG-3. This allows the immune system to more effectively target and destroy cancer cells. The drug is also called BMS-986016 in some clinical trials.

The other drug in is this study is called Nivolumab (Opdivo®); an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. This drug performs a similar role to relatlimab, but does so by targetting a molecule called PD-1.


The Trial:

Patients enrolling on this study will be randomly assigned to one of two groups:

  1. Relatlimab alone
  2. Relatlimab + Nivolumab

The researchers will monitor the safety and effectiveness of each treatment regimen for up to 3 years after completion

Different doses and administration schedules will be used to determine the optimal dosage of these drugs.


Basic Eligibility:

  • All subtypes eligible
  • Cancer has spread or cannot be removed by surgery
  • No prior treatment with immunotherapy
    • (i.e. Nivolumab (Opdivo®) or Pembrolizumab (Keytruda®))

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentrePrincess Margaret Cancer Centre Principal InvestigatorDr Marcus Butler LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreHôpital Hôtel-Dieu de Québec Principal InvestigatorDr Joel Claveau LocationQuébec, QC Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!